SKLB1028, Daunorubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)

This study is testing a new combination of three drugs — SKLB1028, daunorubicin, and cytarabine — as initial treatment (induction therapy) for adults with newly diagnosed acute myeloid leukemia (AML) that has a specific FLT3 gene mutation. **You may be eligible if...** - You are between 18 and 60 years old - You have been newly diagnosed with AML (have not received prior AML treatment) - Your AML tests positive for a FLT3 gene mutation - You are in good enough health to receive intensive chemotherapy - You can swallow the study drug orally **You may NOT be eligible if...** - You have received prior treatment for AML - You are over 60 years old - You have significant liver, kidney, or heart problems - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.